Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter phase Ib/II study of QLP2117 combined with QL2107 in patients with advanced tumors
CTR20251198Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PSB114 in Non-hematologic malignancy, sponsored by Qilu Pharmaceutical. Started May 2025; status: active.
02
Drugs
PSB114
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20251198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251198.